Cargando…
Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
Monoclonal antibodies specific for programmed cell death 1 (PDCD1, best known as PD-1) have been shown to mediate antineoplastic effects in follicular lymphoma patients. However, the relative proportion of intratumoral PD-1(+) T-cell subsets, in particular follicular helper T cells (which exert pro-...
Autores principales: | Chu, Fuliang, Neelapu, Sattva S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011813/ https://www.ncbi.nlm.nih.gov/pubmed/24808975 http://dx.doi.org/10.4161/onci.28101 |
Ejemplares similares
-
Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
por: Deng, Liufu, et al.
Publicado: (2014) -
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013) -
PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017) -
The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
por: Deng, Mi
Publicado: (2019) -
A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
por: Nagato, Toshihiro, et al.
Publicado: (2014)